IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay
IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases.
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid
IGM Biosciences Shares Fall on Strategic Pivot to Autoimmunity, New CEO
Shares in IGM Biosciences fell after the company said it intends to focus exclusively on the treatment of autoimmune diseases, with Fred Schwarzer being replaced as chief executive officer as part of this strategic pivot.
IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation’ to Autoimmune Diseases
Shares of IGM Biosciences were spiraling after the biotechnology company announced “a strategic pivot and pipeline transformation” to focus exclusively on autoimmune diseases. It also appointed Dr. Mary Beth Harler — who joined the company in 2021 after a decade-long career at Bristol Myers Squibb — as chief executive.
IGM Biosciences: Hold Rating Amidst Strategic Shift and Leadership Changes
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of
IGM Biosciences downgraded to Hold, stock falls
IGM Biosciences (NASDAQ:IGMS) was downgraded to Hold from Buy at Truist Securities, as it believes that full scale autoimmune pivot comes with certain uncertainties. IGMS stock down 11.3%. The research broker has also reduced its price target on the company to $12 from $24.
FierceBiotech3d
IGM completes pivot from cancer to autoimmune, shaking up C-suite and hinting at layoffs
IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...
News Medical on MSN17d
IgM antibodies identified as critical for fighting S. aureus infections
Staphylococcus aureus, mostly known from its antibiotic-resistant variant Methicillin-resistant Staphylococcus aureus (MRSA), ...
Seeking Alpha16d
IGM Biosciences: Waiting For Godot
The company is focused on developing Immunoglobulin M or IGM antibodies as potential treatments for various cancers, as well as autoimmune and other diseases. IGM antibodies should have ...
Medscape3d
Laboratory Diagnosis of Human Hantavirus Infection: Novel Insights and Future Potential
as well as IgM antibody capture ELISAs. Neutralization test is one tool used for serodiagnosis. This test is the most specific of serological tests, but it is laborious and expensive. POC-PUUMALA ...
Yahoo Finance24d
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head ...